CDF to save NHS £140m over five years

31 January 2018 - At least £140 million is expected to be released into the NHS over the next five ...

Read more →

Cancer Drugs Fund of minimal benefit

6 June 2017 - A new study has concluded that the medicines available in the previous version of the NHS Cancer ...

Read more →

Conservatism and the cancer drugs fund

24 May 2017 - Are some patients—and some people— more deserving than others? ...

Read more →

Cancer fund failure highlights the dilemma of drug pricing

1 May 2017 - The challenge is to keep treatments affordable but still encourage innovation. ...

Read more →

Cancer Drugs Fund condemned as expensive and ineffective

28 April 2017 - Treatments approved by David Cameron’s scheme were not worth money, extended life very little and often had ...

Read more →

NICE approves three quarters of CDF group 1 drugs for routine use

17 November 2016 - More than 75% of treatments in the Cancer Drugs Fund which have been looked at again by ...

Read more →

Japan government panel halves price of cancer drug Opdivo

16 November 2016 - In an unprecedented move, a government panel decided Wednesday to cut the official price of cancer ...

Read more →

Did it matter that the Cancer Drugs Fund was not NICE? A retrospective review

3 October 2016 - This article reviews the means by which the Cancer Drugs Fund made recent funding decisions for cancer ...

Read more →

Cancer Drugs Fund requires further reform

27 September 2016 - Reliance on “real world” observational data undermines evidence base for clinical practice. ...

Read more →

A novel UK approach to cancer access: yes, no, or maybe?

10 August 2016 - What are the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients? ...

Read more →

Cancer patients may lose vital drug in crackdown on funding: watchdog reviews 31 treatments that are not usually available on the NHS

10 August 2016 - The drug brentuximab vedotin may no longer be provided on the NHS. ...

Read more →

Rare cancer drug which significantly delays progression of advanced thyroid cancer is left off relaunched Cancer Drugs Fund

2 August 2016 - People with radioiodine refractory differentiated thyroid cancer are overlooked as Lenvima (lenvatinib mesylate) is not scheduled for ...

Read more →

Make drug makers pay: England’s strategy for cancer medicines

29 July 2016 - Roche, Pfizer concerned new system has no spending limit. ...

Read more →

Cancer sufferers may lose access to effective drugs, says support group

29 July 2016 - Medicine regulator NICE will act as gatekeeper for new treatments, leading to fears NHS patients may be ...

Read more →

New drugs available after Cancer Drugs Fund revamp

30 July 2016 - The NHS has announced new potentially life-saving medicines that will be made available to patients as part ...

Read more →